A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of Pf-03049423 In Subjects With Ischemic Stroke
A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of Pf-03049423 In Subjects With Ischemic Stroke
The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. The study will also explore the relationship between PF-03049423 concentration and blood pressure.
The interim analysis for the POC study A9541004 demonstrated futility, and the study was stopped on the 6th of November 2013. There were no signals of serious safety concern.
Inclusion Criteria:
Exclusion Criteria:
Hershey, Pennsylvania 17033, United States
Sofia, 1431, Bulgaria
Plzen - Lochotin, 304 60, Czechia
Budapest, 1076, Hungary
Seongnam-si, Gyeonggi-do 463-707, South Korea
Anyang-si, Gyonggi-do 431-070, South Korea
Seoul, 120-752, South Korea
Taoyuan County, 333, Taiwan